Partial List of Poster Titles 


Arctic University of Norway (UiT) 

Combating Antibiotic Resistance: Fragment-Based Screening for Class D Beta-Lactamase Inhibitors 


Biogen Idec 

Enabling RORgamma Inverse Agonist Crystallography Through AF2 Reduction 


BioSolveIT, Inc. 

In Silico Drug Discovery for Medicinal Chemists: The 21st Century Has Arrived 


Broad Institute 

Experimental Curation of a Fragment Library Using Self-Aggregation Assays 


Bruker BioSpin 

19F-Detected NMR for Fragment Based Drug Discovery 


Chapman University 

Cyclic Peptide-Drug Conjugates for Tumor Targeting and Treatment 


Chemical Computing Group 

Targeting Specific Interactions to Improve EGFR-Ligand Binding 


Christian Albrechts University 

Photoactivatable Prodrugs of Anti-Melanoma Agent Vemurafenib 


CMDBioscience, Inc. 

Addressing the Proteolytic Stability Problem in the Information Age 


The Development, Validation and Application of CMDInventus to Enable Structure-Based Peptide Drug Design and Discovery 


DiscoveRx Corporation 

HitHunter-Pulse: A Novel Denaturation-Based Screening Approach That Overcomes Limitations of Current HTS Methods 


EDASA Scientific 

2-Phenyl-4,5,6,7-Tetrahydro-1H-Indole Fragments as a Novel Anti-Hepatitis C Virus Research Tools 


Federal University of Rio de Janeiro 

Synthesis and Schistosomicidal Activity of Praziquantel Derivatives for Improvement the Clinical Applicability 


GE Healthcare Biosciences 

Clean Screen: Optimization of a Commercially Available Fragment Library by Identification of Promiscuous Binders by SPR Using Biacore™ Systems 



Discovery of a Novel Smyd3 Inhibitor That Bridges the SAM-and MEKK2-Binding Pockets 


HitGen Ltd. 

Encoded Macrocyclic Libraries as Sources of Novel Protein-Protein Interaction Inhibitors 



A Rational Approach for the Discovery of Inhibitors of the YAP-TEAD Interaction 


Key Organics Ltd. 

Building a Diverse and Experimentally-Curated Fragment Library 


King Saud University 

Structure-Based Design of Phthalimide Derivatives as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Anti-Inflammatory and Analgesic Activities 


Novel Quinolines Carrying a Biologically Active Pyridine, Thienopyridine, Isoquinoline, Thiazolidine, Thiazole and Thiophene Moicties of Expected Anticancer Activity 


Lawrence Berkeley National Laboratory 

Facilitating Drug Discovery Through Microfocus Macromolecular Crystallography at the Advanced Light Source 


Life Chemicals, Inc. 

PPI Inhibitor Screening Compound Libraries 


Fragment Screening Libraries 


Manipal University 

Design, Synthesis and EGFR Tyrosine Kinase Inhibitory Activity of Novel Quinazoline Derivatives 


Synthesis of Some New Indole-Coumarin Hybrids as Bcl-2 Inhibitors and Anticancer Agents 


Malvern Instruments Limited 

Advantages of the Use of MicroCal Auto-ITC200 and Auto Cap DSC in FBDD Campaign: From Secondary Screening to Lead Optimization 


Medical University of South Carolina 

Dual Inhibitors of Lysine-Specific Demethylase (LSD1) and Spermine oxidase (SMO) as Novel, Reversible, Small Molecule Epigenetic Modulators for Use in Cancer and Cardiovascular Diseases 


Meiji Seika Pharma Co. Ltd. 

Protein Signal Selective S1P1 Receptor Agonist with Improved Cardio-Safety 


Midwestern University 

Aspartyl(Asparaginyl)-Beta-Hydroxylase Inhibitors for Treatment of Hepatocellular Carcinoma, Pancreatic Cancer and Cholangiocarcinoma 


National Institutes of Health, National Center for Advancing Translational Sciences 

CD28 and ITK Signals Regulate Autoreactive T Cell Trafficking 


North Carolina State University 

Determination of Drug Residence Times in a HTS Format Using Transcreener ADP2 Assay 


Oswaldo Cruz Foundation, Oswaldo Cruz Institute 

Schistosomiasis Drug Discovery and Development Through High-Content Imaging 


Palacký University 

Polymer-Supported Synthesis of 3,3-Disubstituted Indolinones via Base-Mediated C-Arylation of 2-Nitrobenzenesulfonamides 


Constrained Peptidomimetics: Medium-Sized Fused Bicycles Incorporation into Peptide Backbone 



Novel Bromodomain and Extra Terminal Domain (BET) Family Bromodomain Assays Utilizing AlphaLISA Technology 


Novel Tetra-Ubiquitin Substrates of Different Linkages for More Biologically Relevant Deubiquitinylase Assays Utilizing AlphaLISA Technology 


Promega Corporation 

Detection of JumonjiC Domain-Containing Histone Demethylase Activities with Homogeneous Bioluminescent Succinate Assay 


Kinase Strips for Routine Creations of Inhibitor Selectivity Profiles: A Novel Approach to Targeted and Flexible Profiling 


Redx Oncology Ltd. 

Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) as a Potential Treatment for B-Cell Malignancies and Rheumatoid Arthritis with Proven Efficacy in a Mouse CIA Model 


SARomics Biostructures AB 

Design of Fragment Libraries for Targeting Protein-Protein Interactions 


Selcia Ltd. 

A 'Game Changing' New Antibiotic: The Discovery of Teixobactin 


Shandong University 

Design, Synthesis and Antitumor Evaluation of Novel Histone Deacetylase (HDAC) Inhibitors Equipped with Phenylsulfonylfuroxan Module as Nitric Oxide (NO) Donor 


Sierra Sensors GmbH 

High Throughput SPR Screening and Characterization of Compound and Fragment Binding 


Sookmyung Women's University 

Identification of Indolylacetic Acid Analogs as Peroxisome Proliferator-Activated Receptor Agonists 


Discovery of Quinolinone Analogs as Estrogen Receptor Agonists 


Syncom BV 

Design, Synthesis and SAR of Soluble 4-Fluorophenyl-Imidazole p38alpha MAPK, CK1delta and JAK2 Kinase Inhibitors 


Tallinn University of Technology 

A New Computational Approach for the Conformational Sampling of Cyclic Molecules - Application to Cyclic Peptides 


Taras Shevchenko National University of Kyiv 

Molecular Docking Studies of Protein-Protein Interaction Site on TRPV1 Ion Channel 


Universidad de Navarra 

Setting-Up HTRF Technology for G9a and DNMT1 High-Throughput Screening 


University of Aberdeen 

Scalable Production of Cyanobactin Variants 


University of Alberta 

Fluorescent Probe for Imaging Cyclooxygeanse-2 Expression in Colon Cancer 


Celecoxib-Based Radiotracer for Cyclooxygenase-2 (COX-2) Imaging in Cancer: Synthesis and Biological Evaluations 


University of Illinois at Chicago 

A Scaffold-Hopping Approach to Discovery of Keap1/Nrf2 Inhibitors 


Engineering Natural Functional Groups from Leucine and Isoleucine into "Stapling" Amino Acids 


University of Wisconsin, Madison 

Chemotherapeutic Sensitization by Disruption of the Interaction Between Fanconi Anemia and Bloom Dissolvasome DNA Repair Complexes 


University of Oxford 

Methylation and Cancer: Inhibiting the PRMTs and Looking for New Epigenetic Markers 


University of Tartu 

Discovery of Novel Chikungunya Virus Inhibitors 


University of Texas at El Paso 

Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models 


Uppsala University 

Specific and Sensitive In-Situ Drug Protein Interaction Detection by Rolling-Circle Amplification and Proximity Ligation 


Vanderbilt University 

Discovery of Small-Molecule Inhibitors of Mcl-1 Using Fragment-Based Methods and Structure-Based Design 


Yonsei University 

Discovery and Development of Thieno[2,3-d]Pyrimidine Derivatives for FLT3 Inhibitor Based on Fragment Libraries of IKK Beta Inhibitors 





Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by March 20, 2015. 

Register online, or by phone, fax or mail.  Please indicate that you would like to present a poster.  Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool.  Please see below for more information. 

Reasons you should present your research poster at this conference:

  • Your poster will be exposed to our international delegation 
  • Receive $50 off your registration 
  • Your poster abstract will be published in our conference materials 
  • Your poster will be automatically entered into poster competition (see below for details) 
  • Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes 

Poster Competition Details:

  • Poster must be submitted by deadline, March 20th
  • Only posters from academic institutions will be judged
  • Two poster winners will be selected based on criteria below
  • Cash prizes will be awarded on last day of event (April 23, Thursday, at end of ‘Walk and Talk Lunch’ in exhibit hall); if winner is not present; award check will be mailed

First round of selection will be based on submitted abstracts and be judged by CHI Conference Directors and their Scientific Advisors. The following criteria will be used:

  • Clarity of abstract
  • Novelty of data
  • Significance for drug discovery

Final round will be judged on-site based on:

  • Aesthetic quality and visual clarity of poster
  • Clear and engaging oral explanation of poster

Note: Posters should be portrait orientation, with maximum dimensions of 36 inches wide (3 feet) x 48 inches high (4 feet). 

Click here for poster instructions  

Poster inquiries: